ClinicalTrials.gg
CompletedNCT03363906Updated Jul 29, 2019Results posted

A Study of Dulaglutide in Healthy Participants

A Phase 1 interventional study of Dulaglutide (Reference) and Dulaglutide (Test) in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-29.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate a new formulation of dulaglutide (study drug) administered under the skin as one injection using a single dose pen compared to three injections using a pre filled syringe.

This study will evaluate how much of the study drug enters the body and how long it takes the body to get rid of it. Information about any side effects that may occur will also be collected.

The study will last about 84 days, including screening and will require overnight stays in the clinical research unit (CRU).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Overtly healthy as determined by medical history and physical examination at time of screening
  • Have a of greater than or equal to (≥) 23 kilograms per meter squared (kg/m²) inclusive

Exclusion criteria

Exclusion Criteria:

  • Have known allergies to dulaglutide, glucagon-like peptide-1 (GLP-1) related compounds, or any components of the formulation
  • Have family history of medullary thyroid cancer (MTC) or a genetic condition that predisposes to MTC
  • Have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis) or gastrointestinal disorder (e.g., relevant esophageal reflux or gall bladder disease) or any gastrointestinal disease which impacts gastric emptying (e.g., gastric bypass surgery, pyloric stenosis, with the exception of appendectomy) or could be aggravated by GLP-1 analogs
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Dulaglutide (Reference)

    Dulaglutide 4.5 mg administered subcutaneously (SC) in 3 prefilled syringes (PFS) in one of two study periods

    Drug: Dulaglutide (Reference)

  • Experimental
    Dulaglutide (Test)

    Dulaglutide 4.5 mg administered SC in 1 single dose pen (SDP) in one of two study periods

    Drug: Dulaglutide (Test)

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Dulaglutide

    Pharmacokinetics was assessed in healthy participants to determine the area under the concentration time curve from 0 to infinity (AUC\[0-∞\]) of Dulaglutide.

    Time frame: Periods 1 and 2: Day 1 - 8 and Day 15: Predose, 24, 48, 72,96,120,144,168, and 336 hours post dose; Follow Up: Day 28

  2. PK: Maximum Observed Drug Concentration (Cmax) of Dulaglutide

    Pharmacokinetics was assessed in healthy participants to determine the maximum observed drug concentration (Cmax) of Dulaglutide.

    Time frame: Periods 1 and 2: Day 1 - 8 and Day 15: Predose, 24, 48, 72,96,120,144,168, and 336 hours post dose; Follow Up : Day 28

07

Results

Posted Jul 29, 2019

Participant flow

Period 1 (Reference or Test)
Participant flow — Period 1 (Reference or Test)
MilestoneSequence A Dulaglutide (Reference) Then Dulaglutide (Test)Sequence B Dulaglutide (Test) Then Dulaglutide (Reference)
Started1512
Received at least one dose of study drug1511
Completed1410
Not completed12
Withdrew: Adverse event12
Period 2 (Test or Reference)
Participant flow — Period 2 (Test or Reference)
MilestoneSequence A Dulaglutide (Reference) Then Dulaglutide (Test)Sequence B Dulaglutide (Test) Then Dulaglutide (Reference)
Started1410
Received at least one dose of study drug129
Completed109
Not completed41
Withdrew: Adverse event20
Withdrew: Withdrawal by subject11
Withdrew: Lost to follow-up10

Outcome measures

PrimaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Dulaglutide

Pharmacokinetics was assessed in healthy participants to determine the area under the concentration time curve from 0 to infinity (AUC\[0-∞\]) of Dulaglutide.

Time frame:
Periods 1 and 2: Day 1 - 8 and Day 15: Predose, 24, 48, 72,96,120,144,168, and 336 hours post dose; Follow Up: Day 28
Reported as:
Geometric mean · nanogram.hour/milliliter (ng.h/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Dulaglutide
nanogram.hour/milliliter (ng.h/mL)Dulaglutide (Reference)Dulaglutide (Test)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Dulaglutide37400 ± 3840000 ± 33
Statistical analysis
  • Dulaglutide (Reference) vs Dulaglutide (Test) · Mixed Models Analysis · p = 0.473 · Ratio geometric least squares (ls) mean: 1.04 · 90% CI 0.949 to 1.14
PrimaryPK: Maximum Observed Drug Concentration (Cmax) of Dulaglutide

Pharmacokinetics was assessed in healthy participants to determine the maximum observed drug concentration (Cmax) of Dulaglutide.

Time frame:
Periods 1 and 2: Day 1 - 8 and Day 15: Predose, 24, 48, 72,96,120,144,168, and 336 hours post dose; Follow Up : Day 28
Reported as:
Geometric mean · nanogram/milliliter (ng/mL)
PK: Maximum Observed Drug Concentration (Cmax) of Dulaglutide
nanogram/milliliter (ng/mL)Dulaglutide (Reference)Dulaglutide (Test)
PK: Maximum Observed Drug Concentration (Cmax) of Dulaglutide213 ± 41240 ± 39
Statistical analysis
  • Dulaglutide (Reference) vs Dulaglutide (Test) · ANOVA · p = 0.119 · Mean difference (final values): 1.14 · 90% CI 0.993 to 1.30

Adverse events

Collected over Up to 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dulaglutide (Reference)0/24 (0%)0/24 (0%)15/24 (62.5%)
Dulaglutide (Test)0/23 (0%)0/23 (0%)14/23 (60.9%)
Most frequent other events
Most frequent other events
EventDulaglutide (Reference)Dulaglutide (Test)
NauseaGastrointestinal disorders11/2412/23
VomitingGastrointestinal disorders5/247/23
ConstipationGastrointestinal disorders4/243/23
DizzinessNervous system disorders4/241/23
HeadacheNervous system disorders3/241/23
DyspepsiaGastrointestinal disorders2/242/23
Injection site painGeneral disorders2/242/23

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(years)Dulaglutide Test and Reference
Mean41.7 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)Dulaglutide Test and Reference
Female12
Male15
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dulaglutide Test and Reference
Hispanic or Latino4
Not Hispanic or Latino23
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dulaglutide Test and Reference
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American22
White5
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Dulaglutide Test and Reference
United States27
08

Study locations

1 site
  • Covance Dallas
    Dallas, Texas 75247, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Jun 2018, 5 months.

Results were first posted in Jul 2019, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2017
First posted
Dec 6, 2017
StartActual
Dec 7, 2017
Primary completionActual
Jun 6, 2018
CompletionActual
Jun 6, 2018
Results first posted
Jul 29, 2019
Last update
Jul 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03363906
Responsible party
Sponsor
First posted
Dec 6, 2017
Start date
Dec 7, 2017
Primary completion
Jun 6, 2018
Completion
Jun 6, 2018
Results posted
Jul 29, 2019
Last update
Jul 29, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion